Abbott Wins UK Government Contract to Supply Millions of Laboratory-Based IgG Antibody Tests
By HospiMedica International staff writers Posted on 23 May 2020 |
Image: Abbott`s ARCHITECT platform (Photo courtesy of Abbott)
Abbott (Lake Forest, IL, USA) has been awarded a government contract to supply millions of its laboratory-based IgG antibody tests to National Health Service (NHS) laboratories across the UK over the coming months.
Abbott's SARS-CoV-2 IgG test specifically identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain up to months and possibly years after a person has recovered. The test is designed to detect the IgG antibody specifically as it can better help physicians determine recovery from infection, versus looking at a combination of antibodies.
Abbott's IgG antibody test will be available at NHS laboratories across the UK, using its ARCHITECT i1000SR and i2000SR and Alinity i laboratory instruments. The ARCHITECT system can run up to 100-200 tests per hour to help hospitals and laboratories with reliable antibody testing during the pandemic.
Abbott has shipped 800,000 antibody tests to NHS laboratories, to be used as part of the testing initiative announced by the UK Secretary of State for Health. These tests, alongside the Abbott PCR tests already being used across the NHS, enable the company to support the UK with broad molecular and antibody testing during this pandemic.
"Abbott is proud to support the NHS' COVID-19 antibody testing strategy announced today, with agreement to supply antibody tests to NHS laboratories across the UK," said Mike Clayton, managing director, Northern Europe diagnostics, Abbott. "We have already delivered 800,000 tests to NHS laboratories, so they are prepared to deploy these tests, in line with government direction. Antibody testing is an important next step as we work to get back to our normal lives."
Abbott's SARS-CoV-2 IgG test specifically identifies the IgG antibody, which is a protein that the body produces in the late stages of infection and may remain up to months and possibly years after a person has recovered. The test is designed to detect the IgG antibody specifically as it can better help physicians determine recovery from infection, versus looking at a combination of antibodies.
Abbott's IgG antibody test will be available at NHS laboratories across the UK, using its ARCHITECT i1000SR and i2000SR and Alinity i laboratory instruments. The ARCHITECT system can run up to 100-200 tests per hour to help hospitals and laboratories with reliable antibody testing during the pandemic.
Abbott has shipped 800,000 antibody tests to NHS laboratories, to be used as part of the testing initiative announced by the UK Secretary of State for Health. These tests, alongside the Abbott PCR tests already being used across the NHS, enable the company to support the UK with broad molecular and antibody testing during this pandemic.
"Abbott is proud to support the NHS' COVID-19 antibody testing strategy announced today, with agreement to supply antibody tests to NHS laboratories across the UK," said Mike Clayton, managing director, Northern Europe diagnostics, Abbott. "We have already delivered 800,000 tests to NHS laboratories, so they are prepared to deploy these tests, in line with government direction. Antibody testing is an important next step as we work to get back to our normal lives."
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans